Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 23.5% in February

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 1,300 shares, a drop of 23.5% from the February 13th total of 1,700 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 19,600 shares, the short-interest ratio is presently 0.1 days.

Addex Therapeutics Stock Performance

NASDAQ ADXN opened at $7.46 on Tuesday. Addex Therapeutics has a twelve month low of $6.67 and a twelve month high of $27.90. The stock has a market cap of $7.91 million, a price-to-earnings ratio of -21.94 and a beta of 1.76. The firm’s 50 day moving average price is $7.74 and its two-hundred day moving average price is $8.77.

Hedge Funds Weigh In On Addex Therapeutics

A hedge fund recently bought a new stake in Addex Therapeutics stock. Citadel Advisors LLC acquired a new position in shares of Addex Therapeutics Ltd (NASDAQ:ADXN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 1.14% of Addex Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 16.14% of the company’s stock.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.